Loading...
Arcutis Biotherapeutics Community
NasdaqGS:ARQT Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 39 Fair Values set on narratives written by author
Community Investing Ideas
Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption
Key Takeaways Expansion of ZORYVE indications and partnerships targets underserved populations, supporting sustained revenue and margin improvement through diversification and operating leverage. Demand for innovative non-steroidal treatments and ongoing R&D investments enhance long-term growth, portfolio expansion, and market share amid favorable demographic trends.
0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
AN
US$23.38
n/aintrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
37.18% p.a.
Profit Margin
35.32%
Future PE
15.19x
Share price in 2028
US$28.3